Navigation Links
Lentigen Corporation announces Sale of Lentiviral Vector Manufacturing Business and Change of Name to Opus Bio, Inc.
Date:8/14/2014

GREENWICH, Conn., Aug. 14, 2014 /PRNewswire/ -- Lentigen Corporation, a global leader in lentiviral technology for cell and gene therapy applications, today announced the sale of its lentiviral vector manufacturing business and related assets to Miltenyi Biotec, who will operate through its newly formed, wholly-owned US subsidiary Lentigen Technology, Inc. based in Gaithersburg, MD.

In connection with the transaction, Lentigen Corporation has been renamed Opus Bio, Inc., and has been granted certain rights to deploy lentiviral technology in specified therapeutic indications, for which Lentigen Technology, Inc. shall be the preferred manufacturing supplier.  These rights include specified CAR T-cell based therapies as well as specified therapies for single-gene diseases and disorders.

Chimeric antigen receptor T cell therapy (CAR+ T) technologies have made significant advances during the past several years, as evidenced by consistent clinical results reported by several academic teams.  "We are pleased that Lentigen Corporation has been at the forefront of the lentiviral vector manufacturing innovation that has enabled these advances in the treatment of hematologic malignancies," said David Wetherell, Chairman of Lentigen Corporation.  He added, "this transaction will provide Opus Bio with ongoing access to innovations in lentiviral vector and cell processing technologies, while allowing the company to commit further resources toward the advancement its research and clinical development programs."

Opus Bio intends to make further announcements on the progress of its therapeutic pipeline during the coming months.

Opus Bio is a clinical-stage biotechnology company committed to developing potentially transformative cell therapies for cancer and single gene disorders. The company is backed by Biomark Capital, a life sciences and healthcare investment firm with offices in Greenwich, CT and San Francisco, CA.

Investor and media contact:
Douglas D. Lind, MD
Interim Chief Executive Officer
Opus Bio, Inc.
(203) 769-2348
doug@opusbio.com


'/>"/>
SOURCE Opus Bio, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
2. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
3. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
4. Neogen Corporation Announces 2nd Quarter Results Conference Call
5. Luminex Corporation to Present at JP Morgan Healthcare Conference
6. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
7. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
8. JBT Corporation and Swisslog Enter Into Partnership for Automated Guided Vehicles
9. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
10. Verenium Corporation to Announce Fourth Quarter and Year-End 2011 Financial Results
11. Luminex Corporation to Speak at Joint Department of Defense and Environmental Protection Agency 5th National Bio-Threat Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... 18, 2017 , ... Researchers from a new study are stating that if levels ... prostate cancer treatment, this indicates there is still remaining prostate cancer cells that are more ... PSA test has always been an indicator of whether a man’s prostate cancer is ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... 2017, to sell research and genetic testing lab equipment from two different leading institutes. ... Northwest and Northeast regions of the United States. This 1-day online auction will ...
(Date:1/18/2017)... ... January 18, 2017 , ... Thirty-six startup companies in University City ... Pennsylvania Department of Community and Economic Development in 2016 as part of the Keystone ... University City Keystone Innovation Zone and represent the highest number of awards to the ...
(Date:1/18/2017)... , Jan. 18, 2017  HUYA Bioscience International, (HUYA), ... China,s pharmaceutical innovations, announced today a ... Innovation and Investment Company (referred to as CAS Innovation). ... innovations discovered by leading scientists at CAS to meet ... HUYA is the first company to have recognized ...
Breaking Biology Technology:
(Date:1/18/2017)... 2017  In vitro diagnostic (IVD) companies were very ... (M&A), and Kalorama Information expects that trend to continue ... shifting. Generally, uncertainty in reimbursement and healthcare reform in ... changed the acquisitions landscape. Instead of looking to buy ... partners outside of their home country and also to ...
(Date:1/12/2017)... -- Trovagene, Inc. (NASDAQ: TROV ), a developer ... it has signed agreements with seven strategic partners across ... Middle East for commercialization of the Trovera™ ... of international distribution agreements for Trovagene,s CLIA based liquid ... The initial partners will introduce Trovagene,s liquid biopsy tests ...
(Date:1/11/2017)... Jan. 11, 2017 Intoxalock, a leading ignition ... release of its patent-pending calibration device. With this new ... calibrations, securely upload data logs and process repairs at ... "Fighting drunk driving through the application of ... at large, but also for the customer who can ...
Breaking Biology News(10 mins):